Le Lézard
Classified in: Health
Subjects: ASI, TRI

Guardant360 CDx submitted for regulatory approval in Japan


TOKYO, Feb. 3, 2021 /PRNewswire/ -- Guardant Health Japan, an affiliate of Guardant Health Asia, Middle East & Africa (AMEA) has announced that it has submitted its application to the Ministry of Health, Labour and Welfare (MHLW) for regulatory approval of Guardant360 CDx, a liquid biopsy test for tumor mutation profiling, also known as comprehensive genomic profiling (CGP) in patients with advanced solid cancerous tumors.

"I am delighted to announce that we have submitted the regulatory application for Guardant360 CDx liquid biopsy test for approval by MHLW. Several clinical studies1,2 have shown that compared to invasive tissue-based testing, Guardant360 has a quicker turnaround time for reporting comprehensive genomic test results. For the patient, this means a shorter waiting time to get the most appropriate treatment while avoiding safety risks related to tissue biopsies. We are excited to make this a possibility in clinical practice for cancer patients in Japan," said Simranjit Singh, Chief Executive Officer of Guardant Health AMEA & Representative Director of Guardant Health Japan.

Guardant360 CDx is a liquid biopsy test that analyzes circulating tumor DNA (ctDNA) from the blood samples of patients with advanced solid tumors and identifies genetic alterations that may inform treatment decisions. In addition to the submission of Guardant360 CDx for tumor mutation profiling, Guardant Health Japan has simultaneously filed for a Companion Diagnostic (CDx) approval. On August 7, 2020, the U.S. Food and Drug Administration (FDA) approved the Guardant360®CDx for comprehensive genomic profiling across all solid cancers and as a companion diagnostic to identify non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) alterations who may benefit from treatment with Tagrisso® (osimertinib). This approval represented the first FDA-approved liquid biopsy test for comprehensive tumor mutation profiling across all solid cancers.

Guardant Health Japan aims to contribute to precision oncology in Japan by supporting research and development efforts and drive broad clinical adoption of Guardant Health's products.

About Guardant Health Japan

Guardant Health Japan is an affiliate of Guardant Health AMEA, Inc., a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics.

References

1. Leighl NB, Page RD, Raymond, VM, et al. Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-Small Cell Lung Cancer, Clin Cancer Res. doi: 10.1158/1078-0432.CCR-19-0624.

2. Nakamura, Y., Taniguchi, H., Ikeda, M. et al. Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. Nat Medicine (2020). https://doi.org/10.1038/s41591-020-1063-5 

Logo

 

SOURCE Guardant Health


These press releases may also interest you

8 fév 2025
Chef&Nutri was born out of the need to encourage healthier living. Focused on the ingestion of nutritionally complete, sustainable and functional foods, based in Bahia, the company is expanding its operations to the Southeast, Midwest and South, in...

8 fév 2025
Joint Announcement of the Teslin Tlingit Council, Government of Yukon, and Government of Canada Today, the Teslin Tlingit Council, the Honourable Gary Anandasangaree, Minister of Crown-Indigenous Relations and Northern Affairs, and the Government of...

8 fév 2025
On Saturday February 8th at 12 noon, the Grey Bruce, Brampton Caledon and Greater Toronto health coalitions, local chapters of the Ontario Health Coalition, will gather outside Minister of Health Sylvia Jones' constituency office to oppose and expose...

8 fév 2025
From February 6 to 9, 2025, the HICC Pet brand is showcasing its groundbreaking grooming and healthcare products at the Hong Kong Convention and Exhibition Centre during the Pet Show Hong Kong 2025. Known as a leader in pet healthcare, HICC Pet...

8 fév 2025
Report on how AI is driving market transformation - The global senior living market  size is estimated to grow by USD 130.9 billion from 2025-2029, according to Technavio. The market is estimated to grow at a CAGR of  5.8%  during the forecast...

7 fév 2025
Report with the AI impact on market trends - The global healthcare services market size is estimated to grow by USD 6.26 trillion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 8.73% during the forecast period....



News published on and distributed by: